Our ScienceThe future of gene editing is now
Beam is a values-driven organization with a vision of delivering lifelong cures to patients suffering from serious diseases.
In 2017, Beam Therapeutics was founded by gene editing pioneers with a goal of creating precision genetic medicines with base editing, a technology discovered at Harvard University and the Broad Institute of MIT and Harvard. Since that time, we have further developed and optimized the technology, which has enabled us to builtd a broad pipeline of investigational precision genetic medicines that have the potential to repair disease-causing point mutations, write in protective genetic variations, or modulate the expression or function of disease causing genes without creating double-stranded cuts in DNA or RNA.
Our goal is to establish the leading platform for precision genetic medicine with a suite of gene editing and delivery technologies. Our manufacturing facility is in North Carolina.
Base Editing
Beam has a growing portfolio of proprietary gene editing technologies, and our current base editor technology includes a cytosine base editor and an adenine base editor.
“Patients are waiting. They need cures and treatments. We believe we have the team and the technology to help deliver on that.”